Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
Nat Commun. 2023 Oct 5;14(1):6206. doi: 10.1038/s41467-023-41941-z.
The impact of a prior SARS-CoV-2 infection on the progression of subsequent infections has been unclear. Using a convenience sample of 94,812 longitudinal RT-qPCR measurements from anterior nares and oropharyngeal swabs, we identified 71 individuals with two well-sampled SARS-CoV-2 infections between March 11, 2020, and July 28, 2022. We compared the SARS-CoV-2 viral kinetics of first vs. second infections in this group, adjusting for viral variant, vaccination status, and age. Relative to first infections, second infections usually featured a faster clearance time. Furthermore, a person's relative (rank-order) viral clearance time, compared to others infected with the same variant, was roughly conserved across first and second infections, so that individuals who had a relatively fast clearance time in their first infection also tended to have a relatively fast clearance time in their second infection (Spearman correlation coefficient: 0.30, 95% credible interval (0.12, 0.46)). These findings provide evidence that, like vaccination, immunity from a prior SARS-CoV-2 infection shortens the duration of subsequent acute SARS-CoV-2 infections principally by reducing viral clearance time. Additionally, there appears to be an inherent element of the immune response, or some other host factor, that shapes a person's relative ability to clear SARS-CoV-2 infection that persists across sequential infections.
先前 SARS-CoV-2 感染对后续感染进展的影响尚不清楚。本研究使用方便样本,对 2020 年 3 月 11 日至 2022 年 7 月 28 日期间 94812 例前鼻和口咽拭子的纵向 RT-qPCR 测量结果进行分析,鉴定出 71 例两次 SARS-CoV-2 感染间隔时间较长的患者。本研究在调整病毒变异、疫苗接种状态和年龄后,比较了这组患者首次和再次感染的 SARS-CoV-2 病毒动力学。与首次感染相比,第二次感染通常具有更快的清除时间。此外,一个人与同一变异株感染的其他人相比,其相对(排名)病毒清除时间在首次和再次感染中大致保持一致,因此首次感染中病毒清除时间相对较快的个体在第二次感染中也倾向于具有较快的清除时间(Spearman 相关系数:0.30,95%可信区间(0.12,0.46))。这些发现提供了证据表明,与接种疫苗类似,先前 SARS-CoV-2 感染产生的免疫通过缩短随后急性 SARS-CoV-2 感染的持续时间,主要通过减少病毒清除时间来缩短后续感染的持续时间。此外,在连续感染中,似乎存在一个影响个体相对 SARS-CoV-2 清除能力的固有免疫反应或其他宿主因素。